I would think that there may have been some deaths

I would think that there may have been some deaths and the CRO checked the records to see if those deaths were patients that had received Brilacidin.

If there had been Brilacidin deaths, I believe the CRO would have suspended the trial until it was determined if the patient was too far gone prior to Brilacidin IV was given and Brilacidin couldn't be positively identified as causing the SAE, but if they determined the deaths were all non-Brilacidin patients they wouldn't have announced or suspended anything as that drug has already shown it doesn't reduce the mortality rate in patients on ventilators.

Bottom line - I take it as a great sign that no suspension of the trial has occurred and we are now at the stage where maybe just a handful (say 5-9) of patients haven't fully received their 5 day dosings of Brilacidin IV. Couple the lack of trial suspension and the ever-increasing rate of patient enrollment thru the trial and IMO I come up with pretty good results are being seen.